FORMULATION OF RECOMBINANT HUMAN LUNG SURFACTANT

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$500,000.00
Award Year:
1988
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Agency Tracking Number:
7315
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
California Biotechnology Inc.
2450 Bayshore Frontage Road, Mountain View, CA, 94043
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
R. Tyler White Phd
(415) 966-1550
Business Contact:
() -
Research Institution:
n/a
Abstract
THE OBJECTIVE OF THE PROPOSED RESEARCH IS FORMULATION OF AN EFFECTIVE SYNTHETIC SURFACTANT TO BE USED IN TREATMENT OF INFANT RESPIRATORY DISTRESS SYNDROME (RDS). RDS IS CAUSED BY INADEQUATE LEVELS OF LUNG SURFACTANT AT BIRTH, AND IS PRESENTLY TREATED BY ASSISTING THE NEWBORN WITH MECHANICAL RESPIRATION, A THERAPY AVAILABLE ONLY AT A LIMITED NUMBER OF MEDICAL CENTERS, AND ONE WHICH CAN SEVERLY DAMAGE THE LUNGS. TREATMENT OF RDS USING NATURAL LUNG SURFACTANT SUPPLEMENTS APPEARS TO BE EFFECTIVE, BUT IS STRICTLY LIMITED BY THE SCARCITY OF HUMAN SURFACTANT PROTEINS, WHICH IN ADDITION TO PHOSPHOLIPIDS, ARE KEY COMPONENTS OF SURFACTANT. THE APPLICATION OF RECOMBINANT DNA TECHNIQUES TO ISOLATE AND EXPRESS THE GENES FOR THE HUMAN SURFACTANT PROTEINS SHOULD PROVIDE UNLIMITED QUANTITIES OF SYNTHETIC SURFACTANT, FORMULATED WITH RECOMBINANT PROTEINS AND PURE PHOSPHOLIPIDS.ONE OF THE TWO MAJOR SURFACTANT PROTEINS (SP28-36) HAS ALREADY BEEN CLONED AND EXPRESSED BY RECOMBINANT DNA METHODS. CALIFORNIA BIOTECHNOLOGY, INC. PROPOSES TO ISOLATE AND EXPRESS THE GENE FOR THE REMAINING HUMAN SURFACTANT PROTEIN, SP17.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government